Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852865 | 0.89 | LMNA (0.53) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2852910 | 0.84 | RAB9A (0.62) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2848793 | 0.82 | MAPT (0.54) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL5788650 | 0.82 | NPC1 (0.67) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL13302673 | 0.80 | TAS1R3 (0.63) | RAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL4488971 | 0.78 | RAB9A (0.62) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL16684621 | 0.76 | ALDH1A1 (0.64) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL8820375 | 0.76 | MAPT (0.56) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL31530471 | 0.76 | RAB9A (0.57) | MAPTRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2853682 | 0.74 | RAB9A (0.55) | MAPTRAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2100875-B1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | TAKASAGO PERFUMERY CO LTD (JP) | 2016-11-16 | — | — | EP | disclosed |
| EP-1685092-B1 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | TAKASAGO PERFUMERY CO LTD (JP) | 2010-01-13 | — | — | EP | disclosed |
| US-7626034-B2 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-12-01 | — | — | US | disclosed |
| EP-2100875-A1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | Takasago International Corporation (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-20070142443-A1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2007-06-21 | — | — | US | disclosed |
| EP-1685092-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | Takasago International Corporation (JP) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005028419-A2 | ASYMMETRIC REDUCTIVE AMINATION OF KETO ACID DERIVATIVES FOR PRODUCING AMINO ACID DERIVATIVES | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142443-A1 | Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives | AADAT, BCAT2, BCAT1 | MAPT 3340/4885RAB9A 1424/4885NPC1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.